Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin

被引:6
作者
Narui, Chikage [1 ]
Tanabe, Hiroshi [1 ]
Shapiro, Jason S. [1 ]
Nagayoshi, Yoko [1 ]
Maruta, Takenori [1 ]
Inoue, Momoko [1 ]
Hirata, Yukihiro [1 ]
Komazaki, Hiromi [1 ]
Takano, Hirokuni [1 ]
Niimi, Shigeki [1 ]
Isonishi, Seiji [1 ]
Okamoto, Aikou [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan
来源
IN VIVO | 2019年 / 33卷 / 06期
关键词
Carboplatin; hypersensitivity reactions; ovarian cancer; rechallenge; overall survival; PHASE-III TRIAL; FALLOPIAN-TUBE; CISPLATIN;
D O I
10.21873/invivo.11702
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: Hypersensitivity reactions (HSRs) to carboplatin, a key drug for ovarian cancer patients, are problematic. The aim of this study was to evaluate the efficacy and safety of readministration of platinum agents (PTs) in recurrent ovarian cancer patients who developed HSRs to carboplatin. Patients and Methods: Thirty-one patients with recurrent ovarian cancer who developed HSRs to carboplatin were divided into those who continued to receive PTs in the following cycle (continuation group, n=24) and those in whom either the drug was switched to non-platinum agents (non-PTs) or chemotherapy was ended (discontinuation group, n=7). Outcomes were evaluated based on patients' medical records. Results: The median survival time following HSRs was 28.1 and 15.4 months in the continuation and discontinuation groups, respectively (p=0.018). In the continuation group, a total of 155 cycles of PTs were re-administrated, and 50 cycles (32%) led to recurrent HSRs. There were no recurrent HSRs with a severity of grade 3 or greater. Conclusion: Continuation of PTs in ovarian cancer patients may contribute to improvement in their overall survival without severe recurrent HSRs.
引用
收藏
页码:2045 / 2050
页数:6
相关论文
共 18 条
[1]   Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer [J].
Altwerger, Gary ;
Florsheim, Esther B. ;
Menderes, Gulden ;
Black, Jonathan ;
Schwab, Carlton ;
Gressel, Gregory M. ;
Nelson, Wendelin K. ;
Carusillo, Nina ;
Passante, Terri ;
Huang, Gloria ;
Litkouhi, Babak ;
Azodi, Masoud ;
Silasi, Dan-Arin ;
Santin, Alessandro ;
Schwartz, Peter E. ;
Ratner, Elena S. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (12) :2449-2456
[2]   Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study [J].
Altwerger, Gary ;
Gressel, Gregory M. ;
English, Diana P. ;
Nelson, Wendelin K. ;
Carusillo, Nina ;
Silasi, Dan-Arin ;
Azodi, Masoud ;
Santin, Alessandro ;
Schwartz, Peter E. ;
Ratner, Elena S. .
GYNECOLOGIC ONCOLOGY, 2017, 144 (01) :77-82
[3]   Cancer of the ovary, fallopian tube, and peritoneum [J].
Berek, Jonathan S. ;
Kehoe, Sean T. ;
Kumar, Lalit ;
Friedlander, Michael .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :59-78
[4]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[5]   Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer [J].
Callahan, Megan B. ;
Lachance, Jason A. ;
Stone, Rebecca L. ;
Kelsey, Julie ;
Rice, Laurel W. ;
Jazaeri, Amir A. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (02) :199.e1-199.e5
[6]   Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy [J].
Dizon, DS ;
Sabbatini, PJ ;
Aghajanian, C ;
Hensley, ML ;
Spriggs, DR .
GYNECOLOGIC ONCOLOGY, 2002, 84 (03) :378-382
[7]  
Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
[8]   Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization [J].
Kook, H ;
Kim, KM ;
Choi, SH ;
Choi, BS ;
Kim, HJ ;
Chung, SY ;
Choi, SJN ;
Hwang, TJ .
BONE MARROW TRANSPLANTATION, 1998, 21 (07) :727-729
[9]   Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic Malignancies [J].
Koshiba, H. ;
Hosokawa, K. ;
Kubo, A. ;
Miyagi, Y. ;
Oda, T. ;
Miyagi, Y. ;
Watanabe, A. ;
Honjo, H. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (03) :460-465
[10]   Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions [J].
Lax, Timothy ;
Long, Aidan ;
Banerji, Aleena .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (06) :856-862